Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del‐CFTR

Rationale: In a prior study, lumacaftor/ivacaftor treatment (≤28 d) in patients with cystic fibrosis (CF) heterozygous for F508del-CFTR did not improve lung function. Objectives: To evaluate an optimized lumacaftor/ivacaftor dosing regimen with a longer duration in a cohort of patients heterozygous...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Ann Am Thorac Soc
Egile Nagusiak: Rowe, Steven M., McColley, Susanna A., Rietschel, Ernst, Li, Xiaolei, Bell, Scott C., Konstan, Michael W., Marigowda, Gautham, Waltz, David, Boyle, Michael P.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Thoracic Society 2017
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5461999/
https://ncbi.nlm.nih.gov/pubmed/27898234
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1513/AnnalsATS.201609-689OC
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak